Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of January 31, 2021, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Capital Structure Details
- Issued Share Capital: 5,386,226,012 Ordinary Shares of 25 pence each.
- Treasury Shares: 355,205,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,031,020,062.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports the static capital position as of January 31, 2021, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,031,020,062) to determine notification thresholds under FCA rules.
- Confirm the number of shares held in Treasury (355,205,950) to calculate the free float accurately.
- Review the issued share capital count (5,386,226,012) for accuracy in ownership calculations.